Search the Newsreel

Molson Coors beats second-quarter expectations and maintains full-year outlook

Can of Coors Light ©Adobe Stock Images Molson Coors Beverage Co. (NYSE:TAP) reported second-quarter results that came in ahead of Wall Street expectations, supported by a modest earnings beat, while reaffirming its financial outlook for the full year despite a challenging operating environment. Adjusted …

Molson Coors (NYSE:TAP) Reports Q2 CY2026 In Line With Expectations

Molson Coors (NYSE:TAP) Reports Q2 CY2026 In Line With Expectations Beer company Molson Coors (NYSE:TAP) met Wall Street's revenue expectations in Q2 CY2026, but sales fell by 3.3% year on year to $3.10 billion. Its non-GAAP profit of $1.58 per share was 4.4% above …

Molson Coors Brewing B earnings beat by $0.06, revenue topped estimates

Molson Coors Releases Q2 2026 10-Q Report Highlighting Capital Structure and Restructuring Plans

Molson Coors Beverage Company filed its Q2 2026 Form 10-Q with the SEC on August 6, 2026. The report details the company's share counts, capital structure, and ongoing strategic and restructuring activities. To access the full report, readers are prompted to log in or …

Molson Coors Beverage Company Reports 2026 Second Quarter Results

GOLDEN, Colo. & MONTRÉAL, August 06, 2026--(BUSINESS WIRE)--Molson Coors Beverage Company ("MCBC," "Molson Coors" or "the Company") (NYSE: TAP, TAP.A; TSX: TPX.A, TPX.B) today reported results for the 2026 second quarter. 2026 SECOND QUARTER FINANCIAL HIGHLIGHTS1 Net sales decreased 3.3% reported and 3.6% in …

14,190 Shares in Colgate-Palmolive Company $CL Purchased by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. recently acquired 14,190 shares of Colgate-Palmolive Company (NYSE:CL) worth approximately $1.3 million. This purchase is part of broader institutional interest, with analysts rating CL as a "Moderate Buy" and setting an average price target of $99. Colgate-Palmolive has …

Molson Coors' Q2 GAAP Pretax Income Drops 49% to $283.1M

Molson Coors Brewing (TAP) Surpasses Q2 Earnings and Revenue Estimates

Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Molson Coors Beverage (NYSE:TAP) Releases FY 2026 Earnings Guidance

Molson Coors Beverage (TAP) Earnings Date and Reports 2026 $TAP

4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan

David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, …

Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants

Moleculin Biotech's Chief Science Officer, Donald H. Picker, recently purchased 173,333 shares of common stock and Series I Warrants to acquire an additional 519,999 shares. These transactions occurred on August 3, 2026, as part of a public offering at a combined price of $0.75 …

Earnings Preview: IMDX to Report Financial Results Post-market on August 10

This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.

Quantinno Capital Management LP Acquires 18,511 Shares of Molina Healthcare, Inc $MOH

Quantinno Capital Management LP increased its stake in Molina Healthcare, Inc. (NYSE:MOH) by 43.1% in the first quarter, purchasing an additional 18,511 shares to bring its total holdings to 61,495 shares valued at approximately $8.2 million. Despite this increased investment, analyst sentiment for Molina …

Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET

This article provides financial information for Moleculin Biotech, Inc. (A41SET) on the TradingView platform. It specifically highlights the "Price to sales forward" metric for the company, accessible through the Lang & Schwarz Tradecenter. The content itself is minimalist, primarily serving as a header for …

Janus Henderson Group PLC Purchases 64,455 Shares of Colgate-Palmolive Company $CL

Janus Henderson Group PLC significantly increased its stake in Colgate-Palmolive Company by 108.1% in the first quarter, purchasing 64,455 additional shares, bringing its total holdings to 124,079 shares valued at $10.6 million. The company reported strong Q1 earnings, beating estimates with EPS of $0.99 …

MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)

Bernstein Liebhard LLP has issued a shareholder class action alert against Molecular Partners AG (MOLN), reminding investors of the upcoming September 12, 2022 deadline to file a lead plaintiff motion. The lawsuit, filed in the United States District Court for the Southern District of …

Molecular Partners AG (MOLN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Is Mounting Margin Pressure Ahead of Q2 Results Altering The Investment Case For Molson Coors (TAP)?

Molson Coors Beverage (TAP) is facing cautious analyst expectations ahead of its Q2 earnings release due to concerns over volume trends and cost pressures, leading to projected margin compression. Despite these concerns, the company has reaffirmed its quarterly dividend, signaling a continued focus on …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Molina securities before February 5, 2025, and still hold them, to join the investigation. …

Colgate-Palmolive Q2 GJ 2026: Bruttomarge steigt, GAAP-EPS sinkt

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History

This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an …

Form 144 4D Molecular Therapeutics For: 4 August By Investing.com

This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) on August 4th. The content is brief, primarily serving as a placeholder for the filing information and is surrounded by typical financial news website navigation and market data. The article …

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares

David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, …

Molina Healthcare Inc. stock outperforms competitors despite losses on the day

Molina Healthcare Inc. (MOH) shares dropped 1.75% to $191.36, marking its second consecutive day of losses, despite a strong overall market performance where the S&P 500 and Dow Jones Industrial Average both rose significantly. The article highlights that even with these daily losses, the …

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades

An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. …

4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan

David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), sold 12,415 shares of company stock on August 3, 2026, at a weighted average price of $10.0461 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on January 9, 2026. …

Moleculin Biotech (NasdaqCM:MBRX) Stock Forecast & Analyst Predictions

Moleculin Biotech (MBRX) is forecast to increase earnings by 54.7% and revenue by 74.8% annually, with EPS expected to grow by 75.4%. The company's lead drug candidate, Annamycin, is progressing through pivotal Phase 2/3 MIRACLE trials for relapsed or refractory acute myeloid leukemia (R/R …

Colgate-Palmolive Readies Organization for Agentic Future

Colgate-Palmolive is undergoing a global digital transformation, heavily investing in AI, data, and analytics to create an "agentic future." CEO Noel Wallace detailed efforts to build an internal AI hub, develop data products, and redesign processes with embedded agents to enhance productivity and optimize …

Insight Molecular Diagnostics updates financial calendar ahead of quarterly results webinar

Insight Molecular Diagnostics announced updates to its financial calendar, scheduling its Q2 2026 results webinar for August 10, 2026, at 5 p.m. ET. Additionally, management will participate in the Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This news brief was …

Groupama Asset Managment Cuts Stock Holdings in Colgate-Palmolive Company $CL

Groupama Asset Management significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 90.5% in the first quarter, selling 23,585 shares and retaining 2,464. Despite this, institutional investors collectively own a substantial 80.41% of the company, and analysts maintain a "Moderate Buy" consensus rating with …

Edgestream Partners L.P. Has $1.70 Million Holdings in Colgate-Palmolive Company $CL

Edgestream Partners L.P. significantly increased its stake in Colgate-Palmolive Company (NYSE:CL) by 131% in the first quarter, now holding 19,924 shares valued at approximately $1.70 million. Institutional investors collectively own 80.41% of the company, which recently reported strong quarterly earnings of $0.99 EPS and …

Confluence Investment Management LLC Decreases Stock Holdings in Colgate-Palmolive Company $CL

Confluence Investment Management LLC reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 3.3% in the second quarter, now holding 1,209,372 shares worth $110.875 million, making it their 18th largest position. Despite this decrease, other institutional investors like Norges Bank and Bank of New York …

MOH|Molina Healthcare Inc|Price:194.740|Chg%:-0.880

This article provides a detailed financial and analytical overview of Molina Healthcare Inc (MOH), including its current